Objective Sorafenib is a novel orally available inhibitor of multiple kinases.It has been used in relapsed and refractory FMS-like tyrosine kinase (FLT)-3 positive AML in recent years with favorable outcomes.Thyroiditis and hypothyroidism have been reported in association with sorafenib and other tyrosine kinase inhibitors such as sunitinib but never in acute myeloid leukemias.